Tissue Repair Company Revenue and Competitors

Tissue Repair Company (TRC) is a San Diego biopharmaceutical company with a clinical-stage focus on products that promote tissue repair. Its scientific expertise is broadly based in gene therapy, growth factor biology, tissue regeneration and product development. GAM technology utilizing well characterized growth factor or cytokine genes circumvents the protein delivery and maintenance hurdles in tissue repair and regeneration indications. GAM provides a method of targeting repair and progenitor cells. Any biocompatible matrix, natural or synthetic, may be used; the formulation selected will depend upon the local environment and the particular clinical indication. TRC’s lead product candidate, EXCELLARATE, is a proprietary DNA-based, collagen matrix gel for topical treatment formulated with an adenovector carrier that encodes for human Platelet-Derived Growth Factor-B (PDGF-B). EXCELLARATE has been studied in an initial multi-center Phase 1/2 clinical trial that evaluated preliminary safety and included an assessment of healing. Based on the data from this 12-patient study, Excellarate appeared to be safe and well tolerated with over 80% of patients showing complete wound closure by 14 weeks based on a single dose or a single weekly dose application over a four-week period. TRC is currently conducting a Phase 2b Study of GAM501 in the Treatment of Diabetic Ulcers of the Lower Extremities (MATRIX).